M Meelu, MD
Hematology & Oncology · Waldorf, MDNPI 1255489027
Payments from drug & device makers
Across 857 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Johnson & Johnson$2K
- AstraZeneca$1K
- Pfizer$1K
- E.r. Squibb & Sons, L.L.C.$764
- Bristol Myers Squibb$710
- plus $9K from 54 others
What the payments were for
- Food & beverage$15,68482%
- Education$1,0195%
- Other$2,52813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ESPRIT$112
How this compares
$19,232 in reported general payments places this provider in the 55th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 31 | $612,496 |
| RevlimidLenalidomide | 32 | $543,668 |
| PomalystPomalidomide | 19 | $439,212 |
| KeytrudaPembrolizumab | 28 | $312,387 |
| OpdivoNivolumab | 23 | $299,311 |
| OnivydeIrinotecan Liposomal | 14 | $282,522 |
| EliquisApixaban | 244 | $225,471 |
| BrukinsaZanubrutinib | 16 | $218,939 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 32 | $210,618 |
| ErleadaApalutamide | 14 | $206,830 |
| KisqaliRibociclib Succinate | 13 | $182,901 |
| XgevaDenosumab | 53 | $176,074 |
| RetacritEpoetin Alfa-Epbx | 89 | $174,585 |
| TavalisseFostamatinib Disodium | 12 | $173,422 |
| XtandiEnzalutamide | 11 | $160,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Opdivo | $764 | $738,52342 claims |
| Bristol Myers SquibbRevlimid | $710 | $543,66832 claims |
| NovartisSandostatin Lar Depot, Kisqali, Adakveo | $3,619 | $542,05063 claims |
| Johnson & JohnsonErleada, Xarelto, Procrit | $1,980 | $406,488120 claims |
| PfizerEliquis, Retacrit | $1,079 | $400,057333 claims |
| MerckKeytruda | $299 | $312,38728 claims |
| Ipsen Biopharmaceuticals, IncOnivyde | $182 | $282,52214 claims |
| Beigene USA, Inc.Brukinsa | $137 | $218,93916 claims |
| AmgenXgeva | $562 | $176,07453 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $384 | $173,42212 claims |
| Astellas Pharma US IncXtandi | $577 | $160,15511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $487 | $109,20312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Waldorf
- Robert KreitmanOlney$54.2M
- Ralph BocciaBethesda$12.1M
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Giuseppe GiacconeBethesda$5.4M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Tim GretenBethesda$4.2M
- Patrick FordeBaltimore$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.